The core mechanism of action of IGF-1 LR3 IGF-1 LR3 activates downstream signaling pathways (such as the AKT/mTOR pathway) by binding to the IGF-1 receptor (IGF1R) on the cell surface, regulating cell proliferation, differentiation, migration, and metabolism

Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides

Syringes or pipettes: Use these for accurate measurement of the solvent volume
This year's findings zero in on the patients who may see optimal weight loss but still experience treatment-limiting side effects